Worth a read...

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
biopearl123
Posts: 458
Joined: Fri Jul 20, 2018 5:13 pm

Worth a read...

Post by biopearl123 » Wed Sep 16, 2020 9:00 pm

https://ascopubs.org/doi/abs/10.1200/JC ... suppl.7507

Ryan saw your response on YMB and found it reassuring but not sure it comports with what I am seeing here. Can you help parse this out? Clearly the study cited is a different population than the lower risk MDS Geron PIII but it is notable that on the Clinical Trials site the Forty Seven study has been modified to now include lower risk patients. The next opportunity to hear Dr. Scarlett address this will likely be KOL meeting to follow ASH. No doubt the analysts will be all over him. The fact that Dr. Scarlett has included ASH presentations as a bullet point suggests that he is either confident abstracts will be accepted or he is aware they already have. At this point unless there is some new early lab based studies, Geron can only update the current data and highlight the need to recruit for both P IIIs. Thanks bp

Post Reply